There are notable gap-ups and gap-downs in today's session. Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.
AI Pharma: 2 Paths to AI-Powered Drug Investment AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? The weight-loss drugs space continues to heat up. Here's the latest news from the segment.
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade The analyst is closely watching MariTide, a potential monthly injection to treat obesity.
3 Promising Biotech Stocks for the Long-Term: August 2024 Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q2 2024 GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
